Immunexpress Analysis: $61M Raised
What is Immunexpress?
Rapid immune response-based sepsis diagnostics
Location
Seattle, United States
Employees
11-50
Founded
2006
Product Features & Capabilities
- SeptiCyte® RAPID for rapid sepsis diagnosis
- Compatible with Biocartis Idylla™ platform
- Analyzes gene expression from whole blood
Use Cases
Diagnose sepsis in suspected patients within one hour; Provide actionable results for 100% of patients tested; Support clinicians in emergency and critical care settings; Aid in early identification to reduce mortality; Facilitate timely treatment decisions in hospitals
How much Immunexpress raised
Funding - $61M
Other Considerations
Serves healthcare stakeholders including medical professionals and payers; Focused on reducing mortality rates associated with sepsis; Aims to lower healthcare costs through early detection
See something that needs updating? Suggest edits to this profile.